Reaction
Axial Spondyloarthritis reporting signals
As of the last recalculation, Axial Spondyloarthritis appears in 833 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is CERTOLIZUMAB PEGOL (PRR 178.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Certolizumab Pegol | 419 | 178.7 | 179.4 |
| Bimekizumab | 51 | 63.7 | 63.8 |
| Adalimumab-Adaz | 79 | 41.2 | 41.3 |
| Adalimumab-Fkjp | 58 | 33.6 | 33.6 |
| Adalimumab-Aaty | 53 | 29.8 | 29.8 |
| Naproxen | 72 | 25.0 | 25.0 |
| Infliximab-Dyyb | 25 | 22.0 | 22.0 |
| Secukinumab | 119 | 21.3 | 21.3 |
| Celecoxib | 92 | 19.5 | 19.5 |
| Methimazole | 6 | 19.2 | 19.2 |
| Golimumab | 61 | 19.1 | 19.1 |
| Sulfasalazine | 46 | 15.5 | 15.5 |
| Guselkumab | 8 | 5.6 | 5.6 |
| Ixekizumab | 8 | 5.4 | 5.4 |